PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ropinirole - Restless Leg Syndrome

PAD Profile : Ropinirole - Restless Leg Syndrome

Keywords :
dopamine agonists, non-ergot-derived dopamine receptor agonists
Brand Names Include :
Adartrel, Requip

Traffic Light Status

Status 1 of 1.

Status :
Green
Important Preferred
Formulations :
  • Immediate release tablets
Important Information :
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Evidence Review
01 November 2021

Committee Recommendations

Date
Committee Name
Narrative
07 November 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Ropinirole is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.

Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome

Associated BNF Codes

04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More